The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

doi:10.1038/nutd.2013.9

Paper

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

Published May 1, 2013 · E. Wargent, M. Zaibi, C. Silvestri

Nutrition & Diabetes

Q1 SJR score

93

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Very Rigorous Journal

Highly Cited

Study Snapshot

THCV is a potential treatment for obesity-associated glucose intolerance, improving glucose tolerance and insulin sensitivity without consistently affecting plasma lipids.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

References

Citations